acetic acid 3-(2-benzoyl-4-ethyl-phenoxy)-propyl ester | 912816-40-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: acetic acid 3-(2-benzoyl-4-ethyl-phenoxy)-propyl ester
• CAS: 912816-40-1
• 化学式: C₂₀H₂₂O₄
• 分子量: 326.392
• InChiKey: TYPMMXAWEVMKKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.81
• 重原子数：
  24.0
• 可旋转键数：
  8.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.6
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  acetic acid 3-(2-benzoyl-4-ethyl-phenoxy)-propyl ester 在 sodium hydroxide 、 potassium carbonate 、 caesium carbonate 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(4-(3-(2-Benzoyl-4-ethylphenoxy)propoxy)phenoxy)-2-methylpropanoic acid
  参考文献：
  名称：

  Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile

  摘要：

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-{4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.

  DOI：

  10.1021/jm060617c
• 作为产物：
  描述：

  3-羟基丙基乙酸酯 在 potassium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 acetic acid 3-(2-benzoyl-4-ethyl-phenoxy)-propyl ester
  参考文献：
  名称：

  Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile

  摘要：

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-{4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.

  DOI：

  10.1021/jm060617c